2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The escalating presence of obesity worldwide is anticipated to stimulate the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment marketplace. Obesity, an ailment marked by an extreme surplus of body fat that can detrimentally affect general health, is usually determined by a body mass index (BMI) of 30 or above. The rate of obesity is proliferating globally, fueled by inactive lifestyles, improper diets, and metabolic risks. The treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in obese individuals prioritizes reversing insulin resistance, lowering liver fat, and improving metabolic health via lifestyle modifications and specific therapies. For instance, data from the World Heart Foundation, a Switzerland-based independent global cardiovascular organization, from March 2023, shows about 2.3 billion adults and children across the world are either overweight or obese. Given the prevailing obesity trend, the projections for this figure will likely hit 2.7 billion by 2025. Consequently, the escalating obesity rates are propelling growth in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
#What Growth Opportunities Will Drive the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market’s CAGR Through 2034?
The market size for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) has seen exponential growth in recent times. From a worth of $2.00 billion in 2024, it is set to increase to an estimated $2.60 billion in 2025, with a compound annual growth rate (CAGR) of 30.0%. Factors contributing to this uptrend during the historical period include the escalating occurrence of non-alcoholic steatohepatitis, contemporary dietary practices, consumption of heavily processed foods, inactive lifestyle, and a rise in metabolic diseases prevalence.
The market for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) is poised to witness a substantial increase in the coming years, with projections showing that it will reach a value of $7.38 billion by 2029, growing at an impressive compound annual growth rate (CAGR) of 29.8%. This predicted upsurge is a result of various factors such as the mounting incidence of obesity and conditions associated with it, initiatives towards early detection and treatment, availability of reimbursement options, insurance protection, and heightened consciousness about liver-related disorders. The forecast period is also expected to see several key trends, such as progress in technology, pipeline projects, strategic alliances and cooperations, the advent of personalized treatments and precision therapy, and amplified investment in clinical studies and research.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20876
What Are the Key Market Innovations in theMetabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Over the Coming Years?
Major firms in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are putting their efforts into creating innovative treatments such as liver fibrosis therapies to cater to the needs of patients suffering from metabolic dysfunction-associated steatohepatitis (MASH) and significant to severe liver fibrosis. The main focus of these liver fibrosis treatment solutions is to tackle the root causes of liver damage through lifestyle changes, antiviral drugs, and newly developed antifibrotic treatments, intending to stop or reverse fibrosis progression and enhance liver functioning. As an example, Madrigal Pharmaceuticals, Inc., a biopharmaceutical company based in the US, mentioned in March 2024 about the FDA approving Rezdiffra (resmetirom), the inaugural treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is an oral tablet taken daily that showed efficiency in resolving MASH without any further fibrosis and enhancing liver fibrosis during phase 3 clinical tests. This innovation presents a non-invasive alternative treatment, eliminating the necessity for liver biopsies and significantly gives a boost to patient accessibility and outcomes in managing fatty liver disease.
Who Are the Top Companies Driving Innovation and Growth in theMetabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals
Order Your Report Now For A Swift Delivery:
Which Key Market Segments Comprise the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market and Drive Its Revenue Growth?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –
1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
Which Regions Are Emerging as Leaders in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2025, By The Business Research Company:
Metabolic Disorders Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Global Cardiometabolic Diseases Global Market Report 2025
https://thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Comprehensive Metabolic Panel Testing Global Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
